focus -WSS

focus

author：Wikipedia 2025-10-01 22:17:14 - browse：138

Dr. Peter Marks, Director of the Center for Biologics Evaluation and Research within the Food and Drug Administration, at a hearing — policy coverage from STAT — Peter Marks, director of the FDA's Center for Biologics Evaluation and Research Greg Nash/Pool via AP

WASHINGTON — A top Food and Drug Administration official wants Congress to dedicate full-time staff to emerging pathogens, after the FDA scrambled to find people for Covid-19 priorities like Operation Warp Speed.

“Vaccines were a pretty heavy duty lift during the pandemic,” said Peter Marks, director of the Center for Biologics Evaluation and Research, at a Thursday Politico event. “Rather than having to essentially reassign whole groups of people and disrupt things, the idea is to have a group of people who are constantly working on this.”

There is reason for optimism. Sens. John Hickenlooper (D-Colo.) and Ted Budd (R-N.C.) successfully added an amendment creating that team to a key pandemic preparedness bill that must be reauthorized by the end of September. It would establish this new program within Marks’ division of the FDA, staffed with experts on vaccines, antibodies, diagnostic tests, personal protective equipment, and other medical countermeasures. Among other activities, this team would enhance surveillance programs and prioritize vaccine research and development so that existing platforms can be retooled to fight other viruses.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： Megan Rapinoe shares emotional post following US Women's World Cup exit

WSS

Idaho college killings prosecutors challenge defense's grand jury claims

EPA limits use of carcinogenic gas for sterilizing medical devices

Yogurt drink instead of a colonoscopy? CRISPR bacteria are tested

After Optum profits sink, UnitedHealth makes changes

Treatments for cramps don't cut it. Why aren't there better options?

In boost for rare disease push, AstraZeneca to buy Amolyt Pharma

focus

focus

focus

In Memoriam: Notable people who died in 2023

President Biden's budget: Here's what you might have missed

Heart attack and stroke risk calculators need revising

Readout LOUD podcast: ALS dilemma, first MASH drug, and more

Medical records are filled with copy

Megan Rapinoe shares emotional post following US Women's World Cup exit

Peter Hotez and the public health issue of online harassment

Mark Cuban is blaming the wrong people for high drug costs

Malaria cases in Florida and Texas: Here’s what you need to know

Boston's new lab space is opening empty

leisure time

Amid AI frenzy, a top HHS official's quest to create safeguards

Treatments for cramps don't cut it. Why aren't there better options?

Aspartame and sugar

Boston's new lab space is opening empty

Change Healthcare outage fallout shows need for new oversight

Biogen’s boardroom scandal saddles CEO with first crisis

Wikipedia

entertainment

leisure time

focus